MedCity News December 18, 2024
Katie Adams

This week, the FDA granted clearance to Withings’ BPM Pro 2 cellular blood pressure monitor. The device seeks to help providers scale remote patient monitoring for heart failure patients.

As chronic heart failure remains a leading cause of death in the U.S., medical device companies continue to release innovative products to help people better manage the disease.

This week, the FDA granted clearance to one of these new innovative devices: Withings’ BPM Pro 2 cellular blood pressure monitor. The device — which France-based Withings originally released in October — is designed to help providers scale remote patient monitoring for heart failure patients.

Historically, providers addressed hypertension mainly through medication, and they adjusted these dosages based on a blood pressure...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Digital Health, FDA, Govt Agencies, Patient / Consumer, Provider, Technology, Wearables
Related Articles:
FDA warns GLP-1 compounder over safety rules
GLP-1 drug approvals: A breakdown
Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Certainty vs. speed: How do patients feel about the tradeoff for new cancer drugs?

Share This Article